Tinengotinib (TT-00420)

tinengotinib · TransThera Sciences (Nanjing), Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Tinengotinib (TT-00420), covering 2025-07-24 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer [Phase 1, Phase 2]

See pricing